-
May 10, 2013
Dendreon looks increasingly irrelevant as the medical community moves on from Provenge.
-
February 14, 2013
Alexion Pharmaceuticals Inc.'s (ALXN) fourth quarter 2012 earnings (excluding special items but including ...
-
February 12, 2013
Recently, Celgene Corporation (CELG) announced that the US Food and Drug Administration (FDA) will review the ...
-
February 12, 2013
MannKind Corporation's (MNKD) loss of 23 cents per share in the fourth quarter of 2012 was wider than the Zacks ...
-
February 11, 2013
Recently, Gilead Sciences, Inc. (GILD) completed its acquisition of Canada-based drug development company, YM ...
-
February 11, 2013
The US Food and Drug Administration (FDA) recently delivered encouraging news to Celgene Corporation (CELG) by ...
-
February 07, 2013
Medivation, Inc. (MDVN) recently announced that its partner Astellas Pharma Inc. (ALPMY) reported Xtandi ...
-
February 06, 2013
Vertex Pharmaceuticals Inc. (VRTX) recently announced that the Health Service Executive (HSE) in the Republic of ...
-
February 05, 2013
Alnylam Pharmaceuticals Inc. (ALNY) recently entered into an exclusive global alliance with The Medicines Company ...
-
February 05, 2013
Gilead Sciences, Inc.'s (GILD) fourth quarter 2012 earnings (excluding special items but including stock option ...
-
February 01, 2013
Global genetic devices maker, Affymetrix Inc.'s (AFFX) fourth-quarter 2012 adjusted loss of 2 cents per share was in ...
-
January 31, 2013
Pluristem Therapeutics, Inc. (PSTI) recently announced that it has taken possession of its new state-of-the-art ...
-
January 30, 2013
The US Food and Drug Administration (FDA) recently approved Kynamro (mipomersen sodium) injection developed by ...
-
January 30, 2013
Vertex Pharmaceuticals Inc. (VRTX) posted a loss of 9 cents per share (including stock-based compensation expense) ...
-
January 25, 2013
Gilead Sciences Inc. (GILD) recently initiated the first of two phase III studies on tenofovir alafenamide (TAF). ...
-
January 25, 2013
Celgene Corporation (CELG) recently announced that its oncology drug, Abraxane, has performed well in a phase III ...
-
January 25, 2013
Biogen Idec (BIIB) recently announced positive top-line data on its phase III multiple sclerosis candidate, ...
-
January 24, 2013
Celgene Corporation's (CELG) fourth quarter 2012 earnings (excluding special items but including stock-based ...
-
January 23, 2013
Arena Pharmaceuticals Inc. (ARNA) recently received 'The Day 180 List of Outstanding Issues' from the European ...
-
January 15, 2013
Shares of Celgene Corporation (CELG) hit a 52-week high of $97.71 almost at the end of the trading session on Jan ...
